In clinical trials in humans with nasopharyngeal carcinoma, the EGFR-TKI cetuximab in combination with chemotherapeutic agents (carboplatin, cisplatin) and/or radiotherapy resulted in comparably favorable survival times with controllable side effects (71–75). Here, EGFR is linked to nasopharyngeal carcinoma.